These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 4554067)

  • 1. Studies with rubella vaccine (RA 27-3) using the subcutaneous and intranasal routes.
    Moffat MA; Gould JJ; Forbes FA; Freestone DS; Macdonald A
    Scott Med J; 1972 Apr; 17(4):140-2. PubMed ID: 4554067
    [No Abstract]   [Full Text] [Related]  

  • 2. Subcutaneous and intranasal administration of RA 27-3 rubella vaccine. Alone and in conjunction with live attenuated measles vaccine.
    Saidi S; Naficy K
    Am J Dis Child; 1969 Aug; 118(2):209-12. PubMed ID: 5794816
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunisation of schoolchildren with rubella (RA27-3) vaccine. Intranasal and subcutaneous administration.
    Ingalls TH; Plotkin SA; Philbrook FR; Thompson RF
    Lancet; 1970 Jan; 1(7638):99-101. PubMed ID: 4188770
    [No Abstract]   [Full Text] [Related]  

  • 4. Vaccination with RA 27-3 rubella vaccine.
    Buser F; Nicolas A; L'Etoile M
    Am J Dis Child; 1971 Jul; 122(1):53-6. PubMed ID: 5567406
    [No Abstract]   [Full Text] [Related]  

  • 5. Intranasal vaccination with RA 27-3 attenuated rubella virus.
    Puschak R; Young M; McKee TV; Plotkin SA
    J Pediatr; 1971 Jul; 79(1):55-60. PubMed ID: 5091268
    [No Abstract]   [Full Text] [Related]  

  • 6. Prevention of rubella during an epidemic on Taiwan. HPV-77 and RA 27-3 rubella vaccines administered subcutaneously and intranasally HPV-77 vaccine mixed with mumps and-or measles vaccines.
    Beasley RP; Detels R; Kim KS; Gale JL; Lin TL; Grayston JT
    Am J Dis Child; 1969 Aug; 118(2):301-6. PubMed ID: 4893832
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical experience with Cendehill rubella vaccine in mature women.
    Farquhar JD; Corretjer JE
    Am J Dis Child; 1969 Aug; 118(2):266-8. PubMed ID: 4893830
    [No Abstract]   [Full Text] [Related]  

  • 8. Antibody response in serum and nasopharynx after naturally acquired and vaccine-induced infection with rubella virus.
    Ogra PL; Kerr-Grant D; Umana G; Dzierba J; Weintraub D
    N Engl J Med; 1971 Dec; 285(24):1333-9. PubMed ID: 4107718
    [No Abstract]   [Full Text] [Related]  

  • 9. Attenuated rubella vaccine (HPV-77): evaluation in a large controlled trial.
    Lipman RP; Bethel MB; Wooten JH; Levine RH; Pagano JS
    Am J Public Health; 1971 Jul; 61(7):1392-402. PubMed ID: 4935166
    [No Abstract]   [Full Text] [Related]  

  • 10. Vaccination of infants with HPV-77 vaccine.
    Pavilanis V; Chagnon A; Davignon L; Joncas J
    Am J Dis Child; 1969 Aug; 118(2):247-51. PubMed ID: 4978509
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparative trial of HPV-77, DE-5 and RA 27-3 live-attenuated rubella vaccines.
    Wallace RB; Isacson P
    Am J Dis Child; 1972 Oct; 124(4):536-8. PubMed ID: 4562789
    [No Abstract]   [Full Text] [Related]  

  • 12. Attenuated rubella virus vaccines in children with tuberculosis. Clinical trials.
    Boué A; Celers J
    Am J Dis Child; 1969 Aug; 118(2):258-60. PubMed ID: 4893827
    [No Abstract]   [Full Text] [Related]  

  • 13. Antibody response in school children to live rubella vaccine (Cendehill strain).
    Iwakata S; Elkerton LE; Rhodes AJ; Bull JA; Labzoffsky NA
    Can Med Assoc J; 1972 May; 106(9):980-2. PubMed ID: 4554732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rubella vaccination during an epidemic.
    Furukawa T; Miyata T; Kondo K; Kuno K; Isomura S; Takekoshi T
    JAMA; 1970 Aug; 213(6):987-90. PubMed ID: 5468562
    [No Abstract]   [Full Text] [Related]  

  • 15. An open community trial of live rubella vaccines. Study of vaccine virus transmissibility and antigenic efficacy of three HPV-77 derivatives.
    Veronelli JA
    JAMA; 1970 Sep; 213(11):1829-36. PubMed ID: 4917635
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparative trials of RA 27-3 and Cendehill rubella vaccines in adult and adolescent females.
    Fogel A; Moshkowitz A; Rannon L; Gerichter CB
    Am J Epidemiol; 1971 May; 93(5):392-8. PubMed ID: 5556399
    [No Abstract]   [Full Text] [Related]  

  • 17. Vaccination of adults with Wistar RA 27/3 rubella vaccine.
    Freestone DS; Prydie J; Smith SG; Laurence G
    J Hyg (Lond); 1971 Sep; 69(3):471-7. PubMed ID: 5285946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Children immunized with HPV-77 rubella vaccine. Additional laboratory observations.
    Katz SL; Lang DJ; Wilfert CM; Feigin RD; Goldfein M
    Am J Dis Child; 1969 Aug; 118(2):213-7. PubMed ID: 4893822
    [No Abstract]   [Full Text] [Related]  

  • 19. Artificial challenge studies in rubella. Utilization of RA 27-3 rubella vaccines, rubella naturally acquired seropositives, and rubella susceptible children.
    Naficy K; Nategh R; Ahangary S; Mohsenin H
    Am J Dis Child; 1970 Dec; 120(6):520-3. PubMed ID: 5481902
    [No Abstract]   [Full Text] [Related]  

  • 20. Viral shedding in Chinese children following vaccination with HPV-77 and Cendehill-51 live attenuated rubella vaccines.
    Detels R; Kim KS; Gale JL; Grayston JT
    Am J Epidemiol; 1971 Nov; 94(5):473-8. PubMed ID: 4941155
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.